ArticleTherapeutic advances in psychopharmacology2013
The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.
Article in Therapeutic advances in psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 5 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Relevance of diet in schizophrenia: a review focusing on prenatal nutritional deficiency, obesity, oxidative stress and inflammation.Frontiers in nutrition · 2024Pooled it
- The role of anti-inflammatory diets and supplementation in metabolic syndrome and symptom remission in adults with schizophrenia: a systematic review.Frontiers in psychiatry · 2024Pooled it
- The role of pharmacy in the management of cardiometabolic risk, metabolic syndrome and related diseases in severe mental illness: a mixed-methods systematic literature review.Systematic reviews · 2021Pooled it
- Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.The British journal of psychiatry : the journal of mental science · 2017Pooled it
- Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.BMC psychiatry · 2016 · on this mapPooled it
- Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- The Role of Cytochrome P450 Holoenzyme Metabolism in the Origin of Neuropathologies.International journal of molecular sciences · 2026Review
- The Economic Impact of Cumulative Metabolic Comorbidity Burden in Schizophrenia: A Claims-Based Analysis of Medical Costs in the United States.Neurology and therapy · 2026Article
- MicroRNAs in metabolic effects with atypical antipsychotics-a scoping review.Therapeutic advances in psychopharmacology · 2026Review
- Pharmacogenetic study of antipsychotic-induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association Study.Translational psychiatry · 2025Article
- Anthropometric and Physiological Measures in Individuals With At-Risk Mental State (ARMS) Compared With Individuals With Schizophrenia: Findings From a Lower Middle-Income Country.Early intervention in psychiatry · 2025Article
- Elevated serum IL-17 A and CCL20 levels as potential biomarkers in major psychotic disorders: a case-control study.BMC psychiatry · 2024Article
- Biomolecular Actions by Intestinal Endotoxemia in Metabolic Syndrome.International journal of molecular sciences · 2024Review
- Influencing factors of different metabolic status in hospitalized patients with schizophrenia.Frontiers in psychiatry · 2024Article
- Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance.World journal of psychiatry · 2023Article
- Outpatients with psychotic disorders need physical health-promoting treatment: A cross-sectional multisite study.Heliyon · 2023Article
- Second-generation antipsychotics and metabolic syndrome: a role for mitochondria.Frontiers in psychiatry · 2023Review
- Calorie-restricted diet mitigates weight gain and metabolic abnormalities in obese women with schizophrenia: a randomized controlled trial.Frontiers in nutrition · 2023Article
- Schizophrenia and cardiometabolic abnormalities: A Mendelian randomization study.Frontiers in genetics · 2023Article
- Gastrointestinal and liver disease in patients with schizophrenia: A narrative review.World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS), a constellation of central obesity, hypertension, dyslipidaemia and glucose intolerance, is highly prevalent in individuals with schizophrenia and conveys significant cardiovascular risk and mortality. Associated risk factors are female sex, some ethnic groups, advanced age, long duration of illness, smoking and exposure to antipsychotic agents. The prevalence of MetS varies across countries and psychiatric populations, and its development can be very rapid. Regular monitoring of all features of MetS is the cornerstone of its early detection and management. Future research needs to focus more on genetic determinants of MetS in the context of schizophrenic illness. This review aims to update the reader with the latest knowledge about the prevalence of MetS in schizophrenia and what might be the underlying pathophysiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.